After realizing that improving care for the sickest, most expensive patients is crucial to a high-performing healthcare system, 5 philanthropic organizations joined forces to create “The Playbook: Better Care for People With Complex Needs,” said David Blumenthal, MD, MPP, president of The Commonwealth Fund.
After realizing that improving care for the sickest, most expensive patients is crucial to a high-performing healthcare system, 5 philanthropic organizations joined forces to create “The Playbook: Better Care for People With Complex Needs,” said David Blumenthal, MD, MPP, president of The Commonwealth Fund.
Transcript (slightly modified)
What is the purpose of the collaboration between The Commonwealth Fund, SCAN Foundation, The John A. Hartford Foundation, Robert Wood Johnson Foundation, and the Peterson Center on Healthcare to create The Playbook?
The purpose is to help the country solve one of the most important looming healthcare problems that we have at the current time, and that is how to take better care of the part of the population that is sickest, most in need, and most expensive—and growing all the time because of demographic trends. We believe that you cannot make our healthcare system high-performing unless we take better care of this population.
We started working on that 3 or 4 years ago at The Commonwealth Fund, and then we discovered that some of our colleague philanthropies were also interested in this work. We decided we could do more together than we could separately, so that was really the reason that we came together around this problem.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More